Background: Positive results of randomized trials led to the introduction of FOLFIRINOX in 2012 and gemcitabine with nab-paclitaxel in 2015 for patients with metastatic pancreatic ductal adenocarcinom
Metastatic pancreatic cancer is difficult to treat. Until recently, most patients would be offered treatment with a chemotherapy drug called gemcitabine. However, a large international trial showed th
Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promot
N-S, non-squamous cell carcinoma; TC, paclitaxel+carboplatin; GP, gemcitabine+cisplatin; DOC, docetaxol; PEM, pemetrxed. Features of included agents and studies.
